Christopher Brown Sells 8,358 Shares of 908 Devices (NASDAQ:MASS) Stock

908 Devices Inc. (NASDAQ:MASS) Director Christopher Brown sold 8,358 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.23, for a total transaction of $77,144.34. Following the completion of the transaction, the director owned 805,559 shares in the company, valued at approximately $7,435,309.57. This represents a 1.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Trading Up 0.1%

908 Devices stock traded up $0.01 during trading on Wednesday, hitting $10.02. The company had a trading volume of 858,415 shares, compared to its average volume of 312,253. The stock has a market cap of $378.90 million, a price-to-earnings ratio of -10.02 and a beta of 0.66. 908 Devices Inc. has a 1-year low of $5.03 and a 1-year high of $10.52. The company’s 50 day simple moving average is $8.23 and its 200-day simple moving average is $7.34.

908 Devices (NASDAQ:MASS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. 908 Devices had a negative return on equity of 14.03% and a negative net margin of 62.40%.The company had revenue of $16.07 million for the quarter, compared to analysts’ expectations of $15.37 million. As a group, analysts forecast that 908 Devices Inc. will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP acquired a new position in 908 Devices during the 2nd quarter worth $29,000. Raymond James Financial Inc. acquired a new stake in 908 Devices in the 2nd quarter valued at about $48,000. Intelligence Driven Advisers LLC acquired a new stake in 908 Devices in the 1st quarter valued at about $61,000. Daiwa Securities Group Inc. purchased a new position in shares of 908 Devices in the 2nd quarter valued at about $61,000. Finally, PCM Encore LLC purchased a new position in shares of 908 Devices in the 4th quarter valued at about $62,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MASS has been the subject of a number of research analyst reports. Stifel Nicolaus raised their target price on 908 Devices from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen cut shares of 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research note on Friday. Finally, Roth Capital lifted their price objective on shares of 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, 908 Devices has an average rating of “Hold” and a consensus target price of $12.50.

Key Headlines Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 results exceeded expectations. 908 Devices reported revenue of $16.07 million, up 23% year over year and above the $15.37 million analyst estimate. Its adjusted loss of $0.11 per share was narrower than the expected $0.14 loss and improved from a $0.18 loss a year earlier. 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $68 million to $70 million, lifting the low end of its prior outlook and broadly bracketing the $68.6 million consensus estimate. The outlook excludes potential AVCAD revenue, leaving possible upside if that business contributes. 908 Devices signals 68M-70M 2026 revenue outlook
• Positive Sentiment: Demand and recurring revenue remain key growth drivers. Law-enforcement, defense, and other mission-critical customers are supporting demand for chemical detection devices. Recurring revenue from NIRLab and upgrades such as VipIR may provide additional stability, while management said the adjusted EBITDA loss narrowed by more than half year over year. 908 Devices: Mission Critical Devices Drive Growth
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful evidence of short-selling pressure or potential short-covering demand.
• Negative Sentiment: The company remains unprofitable, with a negative net margin and return on equity. Although losses improved, continued negative EPS and the stock’s sharp recent appreciation could increase valuation sensitivity if growth or guidance disappoints.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.